CJC-1295 (No DAC): Research Peptide Overview, Mechanisms, and Laboratory Applications

CJC-1295 (No DAC), also referenced in the literature as Modified GRF (1-29), is a synthetic 30-amino acid GHRH (growth hormone-releasing hormone) analogue commonly examined in controlled laboratory environments. Unlike the DAC-modified variant, the No DAC form is studied as a short-acting reference compound for GHRH-receptor signalling research. This article provides a research-focused overview of CJC-1295 (No DAC), including its classification, mechanisms under study, and relevance in laboratory settings. What is CJC-1295 (No DAC)? CJC-1295 (No DAC) is a synthetic 30-amino acid peptide based on the first 29 residues of human GHRH with stabilising amino-acid substitutions. The 'No DAC' designation indicates that this variant does not carry the Drug Affinity Complex (DAC) modification that extends half-life in the DAC-bearing analogue. In laboratory settings, it is studied as a short-acting reference compound for investigations involving GHRH-receptor (GHRH-R) signalling. It is classified strictly as a research peptide and is not approved for human or therapeutic use. Research Overview and Mechanisms: Within controlled laboratory environments, CJC-1295 (No DAC) is examined for its interaction with GHRH-receptor signalling pathways. Researchers reference the compound to observe how short-acting GHRH analogues behave under specific in-vitro conditions, including receptor engagement, downstream signalling activity, and pathway-level interaction patterns. Its short-acting profile makes it useful in research models where time-resolved receptor activity is being studied.